Cardiovascular results of an individually controlled complex prevention.

UNLABELLED: Lifestyle modifications (increased level of physical activity, favourable nutrition, and stress management) are important factors in the prevention of and the therapy for cardiovascular (CV) diseases. OBJECTIVES: The effects of an individualized, half-year long exercise program on CV risk factors were investigated in 50 patients with moderately high CV risk factors. PATIENTS AND METHODS: 75 subjects participated in the study. After the eleventh week of regular training, members of Group A performed 55-65 minutes of exercise at 4-5 times a week, while patients in Group B took part in 45-55 minute training sessions at 2-3 times a week. Activities were monitored using POLAR devices and controlled by a cardiologist and an exercise training expert. Members of the control group (C)were also affected by risk factors, they, however, were not involved in any physical activity. RESULTS: A marked improvement was seen in performance level (62% in Group A, 38% in Group B). There was a decrease in the LDL cholesterol level (30% and 21%), total cholesterol (16% and 14%), triglyceride (23% in both groups), and an increase in the HDL-cholesterol level (53% and 26%). Body mass (BM) decreased in both groups (8.7% and 5%).In addition, a decrease was also seen in the resting heart rate (HR) (9.6% and 4.5%) and blood pressure (BP: systolic 8.5% and 5.5 %, diastolic 7% and 4.7%). CONCLUSIONS: In persons affected by CV risk factors, lifestyle modification with personal, HR controlled complex (cardio and resistance) aerobic training effectively decreased CV risk factors and strongly improved state of health and quality of life.

Developmental docosahexaenoic and arachidonic acid supplementation improves adult learning and increases resistance against excitotoxicity in the brain.

Through metabolic imprinting mechanisms a number of bioactive molecules including polyunsaturated fatty acids affect brain functions in the developmental age and longer-lasting beneficial effects are expected. In this study pregnant rats were offered diets either containing no docosahexaenoic acid (DHA) and arachidonic acid (AA) (Placebo diet) or an excess amount of these long chain polyunsaturated fatty acids (LC-PUFA) (Supplement diet) up to the time of weaning. Bilateral N-methyl-D-aspartate (NMDA) induced neurodegeneration in the entorhinal cortex of offspring in the age of 4 months was used as a tool to investigate the neuroprotective property of the developmentally supplemented DHA and AA treatments. Hippocampus-dependent spatial learning was measured in Morris water maze and the extent of neuronal lesion in the injected brain area was evaluated. Under baseline condition, in intact or sham-lesioned rats, the Morris water maze performance was superior in the supplemented group compared to the placebo controls. NMDA-lesion in the entorhinal cortex area decreased spatial learning in the supplement-treated rats while insignificantly diminished it in the placebo controls. The same supplementation attenuated the lesion size induced by the NMDA injection into the entorhinal and ventral hippocampal areas. We concluded that LC-PUFA supplementation during fetal and early postnatal development results in long-term enhancement of spatial learning ability of the offspring and offers resistance against excitotoxic brain lesion which lasts up to the adult age.

Self-admitted behavior and perceived use of performance-enhancing vs psychoactive drugs among competitive athletes.

The relationships between projected use, self-reported behavior and attitudes to performance-enhancing (PED) and recreational (RD) drugs were investigated among 82 competitive Hungarian athletes, with 14.6% admitting using PED and 31.7% using RD. Both the observed doping estimations (even those made by non-users) and self-admitted use were considerably higher than the average rate of positive doping tests (2% of all tests). The notable overestimation by PED users (34.6% vs 16.9%) was in keeping with the false consensus effect. A prediction model with attitude and projection to the likelihood of PED use suggested at least a 70% chance of self-involvement of athletes, with responses at or above the median scores (Performance Enhancement Attitude Scale ≥ 60 and estimation ≥ 50%) on the two independent measures. Users overestimated the prevalence of doping in their sport (P=0.007) but not RD use, with the converse holding for RD users' views of doping (P=0.029). PED users also showed a significantly more lenient attitude toward doping (P<0.001). This domain-specific characteristic adds new information to the ongoing research effort in understanding drug-doping co-morbidity. The reasons for elevated in-group projection are discussed, along with the potential application of this phenomenon in doping epidemiology studies.

Thermoluminescent dose measurements on-board Salyut type orbital stations.

A small, vibration- and shock-resistant thermoluminescent dosemeter /TLD/ system--named PILLE--was developed at the Health Physics Department of the Central Research Institute for Physics, Budapest, to measure the cosmic radiation dose on board orbital stations. The first on-board measurements with this system were performed /by B. Farkas, the Hungarian astronaut/, on the Salyut-6 space station in 1980. The same instrument was used by other crews in the following years. Doses measured at different sites in Salyut-6 are presented. The dose rates varied from 0.07 to 0.11 mGy.day-1. After the first cosmic measurements, the system was further developed. The minimum detectable dose of the new TLD system is 1 microGy, i.e. less by on order of magnitude than that of the former system. The self-irradiation dose rate of the TLD bulbs is also reduced--by more than one order of magnitude--to 10 nGy.h-1, by the use of potassium-free glass for the bulb envelope. This new type of PILLE TLD system is currently on-board Salyut-7. The dose rates /0.12-0.23 mGy.day-1/ measured in 1983 are presented in detail.

A new thermoluminescent dosimeter system for space research.

A small, portable, vibration and shock resistant thermoluminescent dosimeter system was developed to measure cosmic radiation dose on board a spacecraft. The system consists of a small battery-operated reader and a special bulb dosimeter. Doses from 10 microGy up to 100 mGy can be measured. The electrical power consumption of the reader is about 5 W, its volume is about 1 dm3 and its mass is about 1 kg. Details are given for the construction and technical parameters of the dosimeter and reader.